Latest Share Chat

REMOVE ADS

Genflow Biosci Share Chat (GENF)

Genflow Biosci Information

Share Price Information for Genflow Biosci (GENF)

Share Price is delayed by 15 minutes

Get Live Data

2.15 0.00 (0.00%)

Bid:

2.10

Ask:

2.20

Spread: 0.10 (4.762%)

Market Cap: £12.18m

Last checked at -

Intraday Genflow Biosci Share Chart

REMOVE ADS

Some Videos You Might Like

Mike Ralston, CEO at Blenco...

17th March 2026

Blencowe Resources

Blencowe Resources: Beehive...

16th April 2026

Blencowe Resources

What's Hot end of April

28th April 2026

Cleantech Lithium

Chat Filters

You must be logged in to use filters Click here to login

Post Message

Post a Message

You must be logged in to post Click here to login

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".

By posting on our share chat boards you are agreeing to the following:

You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
- discuss illegal or criminal activities.
- post any confidential or price sensitive information or that is not public knowledge.
- post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
- post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
- post any personal details (e.g. email address or phone number).
- post live price or level 2 updates.
- publish content that is not your original work, or infringes the copyright or other rights of any third party.
- post non-constructive, meaningless, one word (or short) non-sense posts.
- post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
- post any affiliate or referral links, or post anything asking for a referral.
- post or otherwise publish any content unrelated to the board or the board's topic.
- re-post premium share chat posts on regular share chat.
- restrict or inhibit any other user from using the boards.
- impersonate any person or entity, including any of our employees or representatives.
- post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
- If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.

The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.

Please note some users may not behave properly and may post content that is misleading, untrue or offensive.

It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.

Premium and Verified Members

Premium Members are members that have a premium subscription with London South East. You can subscribe here.

London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.

Only showing the five most recent posts. Click here to view the whole thread.

Genflow Biosciences is a company focused on longevity and has secured European patent rights for a SIRT6 variant, according to a LinkedIn post from Versetti Family Office.

Versetti Family Office posted about Genflow Biosciences' patent progress, but this doesn't confirm a direct investment; it could be a statement of interest or awareness within the longevity sector.

.....

Longevity: Versetti Family Office's Bold Investments

PRESS RELEASE

Published September 20, 2025

.......

Angel believes that even if lifespan extension is beyond our current scientific possibilities, we could at the very least solve lifespan: "The very least longevity could do is to enable people to reach old age not unlike the society in Brave New World, even if people cannot live longer, at least they can die fit and beautiful, not in misery and slow decay; after all, the biggest argument of the general population against longevity is that they would not want to extend the miserable old years of their lives - let's focus on that, while we seek answers to how to expand lifespan!"

A Future-Oriented Vision

What sets Angel Versetti and Versetti Family Office apart is not only a remarkable track record as biotech and AI investors, but a sense of possibility and "moonshot" thinking at the heart of every venture. Angel himself is a serial entrepreneur having exited multiple successful startups in AI and Web3 domain. He brings his entrepreneurial skillset and passion, as well as that of many of his prior ventures' early employees to his investments. Versetti Family Office maintains an open call to founders working on longevity and AI: bring your boldest ideas and let's shape the future together. Versetti Family Office has earmarked 50 million USD to invest in the boldest commercially viable longevity moonshots.

Leadership & Global Recognition

Angel Versetti's expertise is respected by leaders and policymakers around the world. In summer 2025, he was invited to speak at the UK Parliament as a Roundtable speaker, sharing his insights on innovation, longevity, and the future of healthtech with government officials and top industry figures. This autumn, he will address the Longevity Summit in China and has recently spoken at the AIM Summit in the UAE alongside the former Prime Minister of the UK Boris Johnson and the Minister of Economy of the UAE. These high-profile engagements signal how Angel's opinions are valued across continents by the world's leading governments and experts in longevity and deeptech. He believes governments, especially in most developed and advanced countries have imperative to assure healthy lifespan of their citizens: "Imagine the economic value for the country, if wise and seasoned 100-year old's had the youthfulness, sharpness of mind and energy of 30 year olds - how much the society would benefit; how much stress would be taken from the hospitals and social security networks".

Longevity: Versetti Family Office's Bold Investm

Only showing the five most recent posts. Click here to view the whole thread.

REMOVE ADS

Only showing the five most recent posts. Click here to view the whole thread.

Based on the most recent regulatory announcements, Genflow Biosciences (LSE: GENF) is not experiencing a "sell-off" in the sense of a panic divestment, but rather a strategic exercise of warrants resulting in the creation of new shares.Here is the breakdown of the situation as of May 2026:Warrant Exercise: On May 8, 2026, Genflow announced the exercise of warrants for 30,756,577 new ordinary shares, raising gross proceeds of approximately £359,375 for the company.Purpose: This injection of capital is designed to fund operations, specifically to continue studies on gene therapies for age-related diseases.Significance: While the issuance of new shares technically dilutes existing holdings, the exercise of warrants by investors is sometimes viewed as a sign of confidence in the company's long-term potential, rather than a lack of confidence.Share Structure: Following this, the company's total shares in issue increased, with the new shares expected to start trading around May 13, 2026.Warrant Terms: Some warrants were exercised at an adjusted price of 1.1p, while others were at 1.9p.The recent activity indicates a move to secure funding for development rather than a market-driven sell-off of the shares themselves.Exercise of Warrants and Issue of Equity. - Halifax8 May 2026 — Application has been made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to...HalifaxIssue of Equity - Correction - 12:37:10 02 Oct 2025 - GENF News ...2 Oct 2025 — Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942. The above figure of 493,547,942 shou...London Stock ExchangeGenflow Biosciences PLC Announces Exercise of Warrants and ...8 May 2026 — Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity * LONDON, UK / ACCESS Newswire / May 8, 2026 / Genflow (LSE:GENF)(OTCQB:GENFF) ("Genf...www.pharmiweb.comGenflow Biosciences PLC Announces Exercise of ...8 May 2026 — Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity * LONDON, UK / ACCESS Newswire / May 8, 2026 / Genflow (LSE:GENF)(OTCQB:GENFF) ("Genf...MorningstarGenflow Biosciences PLC Announces Exercise of Warrants and ...8 May 2026 — 28,124,999 new ordinary shares being issued pursuant to the exercise of warrants granted and announced on 8 May 2025. As announced, the exercise price of these ...Yahoo FinanceGenflow Biosciences Share Chat - GENF - ADVFN UK10 May 2026 — moneymunch: Presumably so Griffin, and the same institutions and long term Major Shareholders, participated to provide Genflow with much needed capital at that ...ADVFN UKGenflow Biosciences expands share capital ...8 May 2026 — Genflow raised about £359,375 by issuing over 30 million new shares through warrant exercises. The company's total shares rose to 566 million, strengthening its...TipRanksGenflow Biosciences PLC Announces Exercise of Warrants and ...8 May 2

Only showing the five most recent posts. Click here to view the whole thread.

Only showing the five most recent posts. Click here to view the whole thread.

The following was published by Acuitas last year, and so obviously their R&D is well advanced in this area, and perhaps no surprise they're happy to collaborate with Genflow, covering all costs and R &D expenditure, to progress from the mouse model with Genflow's Sirt6,

compelling and potential panacea payload...Gla holders...a Major re-rate beckons!!!! :-)

July 3rd, 2025

Acuitas Therapeutics Collaborates on mRNA-LNP Prime

Editing Study for Genetic Liver Disease

Vancouver, B.C. – Acuitas Therapeutics today announced its collaboration on a landmark study published in Nature Biomedical Engineering, titled “Treatment of a metabolic liver disease in mice with a transient prime editing approach,” which highlights the therapeutic potential of

lipid nanoparticle (LNP)-mediated mRNA delivery for prime editing in vivo. The study – co-authored by Acuitas scientists Ying Tam, Jennifer Moon, Paulo Lin, and Steven Fan, along with partners from the University of Zurich, ETH Zurich, and the University of Pennsylvania –presents a novel approach to correct a disease-causing mutation in a mouse model of phenylketonuria (PKU), an inherited metabolic liver disorder.

The research team used two distinct strategies for liver-targeted prime editing, both of which delivered the prime editor (PE) as nucleoside-modified mRNA encapsulated in Acuitas’ LNP.

In the first strategy, the guide RNA (pegRNA) was stably expressed from an adeno-associated virus while in the second, the pegRNA was delivered as synthetic RNAs using LNP delivery.

Using these approaches, they achieved up to 47.4% editing at the Dnmt1 locus and up to 20.7% correction of the pathogenic Pahenu2 mutation in PKU mice with the enhanced PE7 variant –successfully reducing blood phenylalanine concentrations below the therapeutic threshold of 360 µmol/L.

The transient nature of mRNA-LNP delivery allowed for high editing efficiency, while minimizing prolonged editor expression and the resultant potential off-target effects, which are concerns with viral delivery systems. These findings highlight the promise of non-viral, mRNA-LNP-based prime editing as a scalable and clinically relevant platform for treating monogenic liver diseases.

A significant and relevant piece of research was published in February this year, which has been gaining traction in the longevity community because it provides the molecular roadmap for exactly what Genflow is attempting with their SIRT6 platform.

Paper Title: "Bidirectional regulation between metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia via liver-muscle crosstalk"

Published in the Journal of Clinical and Translational Hepatology (Released February 11, 2026).

This study effectively proves that MASH (MASLD) and Sarcopenia are not two separate diseases, but a single pathological loop. This is a massive NAV lifter for Genflow because it validates the strategy of using one payload (SIRT6) to treat both conditions.

Key Findings:

The researchers used Mendelian randomization to prove that diminished muscle mass increases the risk of liver disease (MASLD), and hepatic fibrosis, in turn, accelerates muscle wasting. The paper identified specific signaling molecules (myokines and hepatokines) that travel between the two organs. Specifically, it identified CCL2 (a myokine from muscle) as a driver of liver disease and Adrenomedullin (a hepatokine from the liver) as a trigger for sarcopenia.

The "SIRT6-Shaped Hole": While the paper focuses on these mediators, it highlights that epigenetic metabolic homeostasis is the broken regulator in both tissues. This is where Genflow’s SIRT6 comes in — it acts as the "Master Regulator" that can reset the metabolic balance in both the liver (stopping the MASH) and the muscle (stopping the Sarcopenia).

This paper validates the Acuitas Partnership, systemic delivery (LNP) of SIRT6 is needed to hit the liver, while other options work for the muscle. This paper proves you must address both to truly cure either.

By identifying muscle as an endocrine organ that talks to the liver, this paper makes Genflow’s Endocrine Uplift (Claim 25) patent application look incredibly prescient.

For the FDA, showing that your drug targets a proven bidirectional axis is far more compelling than just targeting a single symptom. It suggests a higher probability of clinical success.

Genflow isn't just guessing that SIRT6 helps both; the broader scientific community has just spent the first part of 2026 proving that the liver and muscle are essentially a single therapeutic target.

This validation is likely to mean the ultimate bidding war for Genflow will be a lot more expensive for a Tier-1.

I’ve seen a few articles about competition in the SIRT6/Glaucoma space following recent academic publications (e.g., the SPAM1 activator study). Interestingly this isn't a threat, it’s effective de-risking.

Here is why recent SIRT6 eye research is actually a massive "Buy" signal for Genflow:

1. "Target Validation" is the First Step to a Deal

Big Pharma doesn't buy ideas; they buy validated targets. Independent studies (like the 2024–2026 UTMB research) have now proven that deleting SIRT6 causes optic nerve degeneration, while overexpressing it prevents it. This "Independent Audit" of the science makes the Genflow SIRT6 platform a 'Must-Have' for any Tier-1 looking to enter the glaucoma space.

2. Gene Therapy vs. Small Molecules (The Winner Takes All)

The competitive research (like SPAM1) is mostly focused on small molecule activators.

Small molecules require daily dosing, have systemic side effects, and often lack the punch needed for true neuroprotection.

The Genflow SIRT6 variant is a permanent, cell-specific reboot of the RGCs. Pharma much prefers a long-term curative asset over a daily drop that patients eventually stop taking.

3. The Patent Barrier

Genflow holds the exclusive global license for the core centenarian SIRT6 variant (originally filed by Rochester/Columbia). Any competitor trying to use a high-efficiency SIRT6 gene for glaucoma has to run directly into Genflow’s patent wall. Research into activators only increases the value of the underlying gene that Genflow owns.

4. The Acuitas Multiplier

The Acuitas partnership gives Genflow the world’s best delivery system (LNP/mRNA). While academics are still using older AAV vectors, Genflow is positioning itself to use the most advanced, scalable delivery tech available.

5. The AAO Conference "Shop Window"

By the time Eric Leire presents at the AAO in October, the scientific community will have already reached a consensus: SIRT6 is the key to stopping glaucoma. Genflow won't have to explain why SIRT6 matters; they only have to explain how their patented variant and Acuitas delivery are the best commercial solutions.

Bottom Line: Recent research proves the "Lock" (SIRT6) is real. Genflow owns the best "Key" (Centenarian Variant + Acuitas).

Again, this research is driving the ultimate deal price up.